State Street’s Annovis Bio ANVS Stock Holding History

State Street’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$173K	Buy	77,735 +3,700	+5%	+$10.1K	﹤0.01%	3920
2025 Q4	$256K	Buy	74,035 +35,600	+93%	+$107K	﹤0.01%	3840
2025 Q3	$79.6K	Hold	38,435	–	–	﹤0.01%	4090
2025 Q2	$83.4K	Hold	38,435	–	–	﹤0.01%	4010
2025 Q1	$57.7K	Hold	38,435	–	–	﹤0.01%	4074
2024 Q4	$193K	Buy	38,435 +2,400	+7%	+$17.4K	﹤0.01%	3862
2024 Q3	$290K	Buy	36,035 +6,900	+24%	+$64.7K	﹤0.01%	3730
2024 Q2	$168K	Hold	29,135	–	–	﹤0.01%	3869
2024 Q1	$347K	Buy	29,135 +5,600	+24%	+$61.1K	﹤0.01%	3736
2023 Q4	$440K	Buy	23,535 +4,300	+22%	+$38.1K	﹤0.01%	3666
2023 Q3	$183K	Hold	19,235	–	–	﹤0.01%	3967
2023 Q2	$275K	Hold	19,235	–	–	﹤0.01%	3906
2023 Q1	$296K	Buy	19,235 +2,100	+12%	+$33.9K	﹤0.01%	3931
2022 Q4	$230K	Hold	17,135	–	–	﹤0.01%	4048
2022 Q3	$235K	Hold	17,135	–	–	﹤0.01%	4072
2022 Q2	$194K	Hold	17,135	–	–	﹤0.01%	4210
2022 Q1	$229K	Buy	17,135 +735	+4%	+$10.6K	﹤0.01%	4331
2021 Q4	$288K	Hold	16,400	–	–	﹤0.01%	4197
2021 Q3	$521K	Sell	16,400 -900	-5%	-$51.7K	﹤0.01%	3962
2021 Q2	$1.48M	Buy	+17,300	New	+$799K	﹤0.01%	3597

Other funds holding ANVS

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

State Street's ANVS Position: Q1 2026 in Review

State Street increased its Annovis Bio (ANVS) stake by 5% in Q1 2026, buying an estimated $10.1K and bringing the position to 77,735 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #3920.

State Street first reported a position in ANVS in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.48M in Q2 2021. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

State Street held 77,735 shares of Annovis Bio worth $173K as of Q1 2026.
State Street bought 3,700 Annovis Bio shares in Q1 2026, an estimated $10.1K.
Annovis Bio made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3920 holding.
State Street first reported a position in Annovis Bio in Q2 2021 and has held it in 20 quarters since.
State Street's Annovis Bio position peaked at $1.48M in Q2 2021.
56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.